Search Results for: CDH5

Novel Interactant Symbol Name
Associated Pathways
Binding Drugs
Associated Diseases
Novel PTPN11 protein tyrosine phosphatase non-receptor type 11
  • Interleukin-6 signaling
  • PI3K Cascade
  • MAPK3 (ERK1) activation
  • MAPK1 (ERK2) activation
  • GPVI-mediated activation cascade
  • Prolactin receptor signaling
  • PIP3 activates AKT signaling
  • Spry regulation of FGF signaling
  • Signaling by SCF-KIT
  • GAB1 signalosome
  • Downstream signal transduction
  • PECAM1 interactions
  • Tie2 Signaling
  • Constitutive Signaling by Aberrant PI3K in Cancer
  • Signaling by Leptin
  • Co-inhibition by CTLA4
  • Co-inhibition by PD-1
  • Signal regulatory protein family interactions
  • Netrin mediated repulsion signals
  • Platelet sensitization by LDL
  • Interleukin-3, Interleukin-5 and GM-CSF signaling
  • Interleukin-3, Interleukin-5 and GM-CSF signaling
  • PI-3K cascade:FGFR1
  • FRS-mediated FGFR1 signaling
  • PI-3K cascade:FGFR2
  • FRS-mediated FGFR2 signaling
  • FRS-mediated FGFR3 signaling
  • PI-3K cascade:FGFR3
  • FRS-mediated FGFR4 signaling
  • PI-3K cascade:FGFR4
  • Negative regulation of FGFR1 signaling
  • Negative regulation of FGFR2 signaling
  • Negative regulation of FGFR3 signaling
  • Negative regulation of FGFR4 signaling
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
  • Regulation of IFNG signaling
  • RET signaling
  • Interleukin-20 family signaling
  • MET activates PTPN11
  • Regulation of RUNX1 Expression and Activity
  • Interleukin-37 signaling
  • Activated NTRK2 signals through FRS2 and FRS3
  • Interferon alpha/beta signaling
  • Regulation of IFNA/IFNB signaling
  • Activation of IRF3, IRF7 mediated by TBK1, IKKε (IKBKE)
  • FLT3 Signaling
  • STAT5 Activation
  • Signaling by CSF3 (G-CSF)
  • Signaling by CSF3 (G-CSF)
  • Signaling by CSF1 (M-CSF) in myeloid cells
  • STAT5 activation downstream of FLT3 ITD mutants
  • Signaling by FLT3 ITD and TKD mutants
  • SARS-CoV-2 activates/modulates innate and adaptive immune responses
  • Co-inhibition by BTLA
  • Dodecyltrimethylammonium
  • Metachondromatosis
  • Noonan syndrome and related disorders, including: Noonan syndrome (NS); Leopard syndrome (LS); Noonan syndrome-like with loose anagen hair (NS/LAH); CBL-mutation associated syndrome (CBL); Neurofibromatosis type 1 (NF1); Neurofibromatosis type 2 (NF2); Neurofibromatosis-Noonan syndrome (NFNS); Legius syndrome; Cardiofaciocutaneous syndrome (CFCS); Costello syndrome (CS)
Novel PTPRB protein tyrosine phosphatase receptor type B
  • Neutrophil degranulation
  • {4-[2-BENZYL-3-METHOXY-2-(METHOXYCARBONYL)-3-OXOPROPYL]PHENYL}SULFAMIC ACID
  • (4-{4-[(TERT-BUTOXYCARBONYL)AMINO]-2,2-BIS(ETHOXYCARBONYL)BUTYL}PHENYL)SULFAMIC ACID
  • {4-[2,2-BIS(5-METHYL-1,2,4-OXADIAZOL-3-YL)-3-PHENYLPROPYL]PHENYL}SULFAMIC ACID
  • (4-ETHYLPHENYL)SULFAMIC ACID
  • Razuprotafib
Novel PYGB glycogen phosphorylase B
  • Neutrophil degranulation
  • Glycogen breakdown (glycogenolysis)
  • Pyridoxal phosphate
  • Alvocidib
Novel RND3 Rho family GTPase 3
  • RND3 GTPase cycle
  • Guanosine-5'-Triphosphate
Novel SHC1 SHC adaptor protein 1
  • Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
  • SHC1 events in ERBB2 signaling
  • SHC1 events in ERBB2 signaling
  • SHC1 events in ERBB4 signaling
  • Signalling to RAS
  • Signalling to RAS
  • SHC1 events in EGFR signaling
  • Tie2 Signaling
  • Integrin signaling
  • XBP1(S) activates chaperone genes
  • Interleukin-3, Interleukin-5 and GM-CSF signaling
  • Constitutive Signaling by EGFRvIII
  • RAF/MAP kinase cascade
  • Signal attenuation
  • Insulin receptor signalling cascade
  • Insulin receptor signalling cascade
  • RET signaling
  • Interleukin-15 signaling
  • Interleukin-15 signaling
  • Interleukin-2 signaling
  • Erythropoietin activates RAS
  • Erythropoietin activates RAS
  • Interleukin receptor SHC signaling
  • Constitutive Signaling by Overexpressed ERBB2
  • Signaling by ERBB2 KD Mutants
  • Signaling by ERBB2 ECD mutants
  • Signaling by ERBB2 TMD/JMD mutants
  • Signaling by CSF3 (G-CSF)
  • Signaling by CSF3 (G-CSF)
  • Signaling by CSF1 (M-CSF) in myeloid cells
Novel SMG1 SMG1 nonsense mediated mRNA decay associated PI3K related kinase
  • Nonsense Mediated Decay (NMD) enhanced by the Exon Junction Complex (EJC)
Novel SRC SRC proto-oncogene, non-receptor tyrosine kinase
  • Signaling by ERBB2
  • Nuclear signaling by ERBB4
  • Downregulation of ERBB4 signaling
  • PIP3 activates AKT signaling
  • GAB1 signalosome
  • Downstream signal transduction
  • Constitutive Signaling by Aberrant PI3K in Cancer
  • Integrin signaling
  • GRB2:SOS provides linkage to MAPK signaling for Integrins
  • p130Cas linkage to MAPK signaling for integrins
  • G alpha (s) signalling events
  • G alpha (i) signalling events
  • G alpha (i) signalling events
  • DCC mediated attractive signaling
  • DCC mediated attractive signaling
  • Netrin mediated repulsion signals
  • Regulation of commissural axon pathfinding by SLIT and ROBO
  • RAF activation
  • MAP2K and MAPK activation
  • Signaling by moderate kinase activity BRAF mutants
  • Signaling by high-kinase activity BRAF mutants
  • Signaling by BRAF and RAF1 fusions
  • Paradoxical activation of RAF signaling by kinase inactive BRAF
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
  • MET activates PTK2 signaling
  • InlA-mediated entry of Listeria monocytogenes into host cells
  • Regulation of RUNX1 Expression and Activity
  • RUNX2 regulates osteoblast differentiation
  • Regulation of RUNX3 expression and activity
  • Extra-nuclear estrogen signaling
  • RHOU GTPase cycle
  • Activated NTRK2 signals through FYN
  • Activated NTRK3 signals through PI3K
  • Activated NTRK3 signals through PI3K
  • Long-term potentiation
  • GPER1 signaling
  • Signaling downstream of RAS mutants
  • Signaling by RAF1 mutants
  • Signaling by CSF1 (M-CSF) in myeloid cells
  • Degradation of CDH1
  • Dasatinib
  • RU84687
  • RU79256
  • N6-Benzyl Adenosine-5'-Diphosphate
  • RU85493
  • RU78262
  • Phosphonotyrosine
  • Malonic acid
  • RU83876
  • RU90395
  • RU79072
  • RU78783
  • 1-Tert-Butyl-3-(4-Chloro-Phenyl)-1h-Pyrazolo[3,4-D]Pyrimidin-4-Ylamine
  • PASBN
  • 2-[4-[(Z)-2-Acetamido-3-oxo-3-[[(3S)-2-oxo-1-[(4-phenylphenyl)methyl]azepan-3-yl]amino]prop-1-enyl]-2-formylphenyl]acetic acid
  • PAS219
  • DPI59
  • RU82197
  • Phenylphosphate
  • RU78300
  • RU79073
  • RU82209
  • ISO24
  • RU85053
  • RU78299
  • Oxalic Acid
  • RU78191
  • Citric acid
  • Paratoulene phosphate
  • 4-[(4-METHYL-1-PIPERAZINYL)METHYL]-N-[3-[[4-(3-PYRIDINYL)-2-PYRIMIDINYL]AMINO]PHENYL]-BENZAMIDE
  • Purvalanol A
  • XL228
  • Tirbanibulin
  • Bosutinib
  • 1-[1-(3-aminophenyl)-3-tert-butyl-1H-pyrazol-5-yl]-3-naphthalen-1-ylurea
  • 1-[1-(3-aminophenyl)-3-tert-butyl-1H-pyrazol-5-yl]-3-phenylurea
  • 3-[4-AMINO-1-(1-METHYLETHYL)-1H-PYRAZOLO[3,4-D]PYRIMIDIN-3-YL]PHENOL
  • PD-168393
  • [4-({4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]quinazolin-2-yl}amino)phenyl]acetonitrile
  • PP-121
  • 1-cyclobutyl-3-(3,4-dimethoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine
  • 1-(1-methylethyl)-3-quinolin-6-yl-1H-pyrazolo[3,4-d]pyrimidin-4-amine
  • 2-(4-CARCOXY-5-ISOPROPYLTHIAZOLYL)BENZOPIPERIDINE
  • N-(4-PHENYLAMINO-QUINAZOLIN-6-YL)-ACRYLAMIDE
  • (2E)-N-{4-[(3-bromophenyl)amino]quinazolin-6-yl}-4-(dimethylamino)but-2-enamide
  • Ponatinib
  • Nintedanib
  • Fostamatinib
Novel VIM vimentin
  • Caspase-mediated cleavage of cytoskeletal proteins
  • Striated Muscle Contraction
  • Interleukin-4 and Interleukin-13 signaling
  • RHOBTB1 GTPase cycle
  • Chaperone Mediated Autophagy
  • Late endosomal microautophagy
  • Aggrephagy
  • Developmental Lineage of Mammary Gland Myoepithelial Cells
  • Artenimol
  • Phenethyl Isothiocyanate
CA7 carbonic anhydrase 7
  • Reversible hydration of carbon dioxide
  • Ethoxzolamide
  • Benzthiazide
  • Cyclothiazide
  • Methazolamide
  • Hydroflumethiazide
  • Acetazolamide
  • Zonisamide
  • Diclofenamide
  • Ellagic acid
CDH1 cadherin 1
  • Degradation of the extracellular matrix
  • Degradation of the extracellular matrix
  • Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell
  • Integrin cell surface interactions
  • Apoptotic cleavage of cell adhesion proteins
  • Adherens junctions interactions
  • RHO GTPases activate IQGAPs
  • InlA-mediated entry of Listeria monocytogenes into host cells
  • Regulation of CDH1 Function
  • Regulation of CDH1 mRNA translation by microRNAs
  • Degradation of CDH1
  • Regulation of CDH1 posttranslational processing and trafficking to plasma membrane
  • Formation of definitive endoderm
  • Transcriptional and post-translational regulation of MITF-M expression and activity
  • Regulation of MITF-M-dependent genes involved in extracellular matrix, focal adhesion and epithelial-to-mesenchymal transition
  • Developmental Lineage of Mammary Gland Luminal Epithelial Cells
  • Developmental Lineage of Mammary Gland Myoepithelial Cells
  • Developmental Lineage of Mammary Stem Cells
  • Penile cancer
  • Breast cancer
  • Gastric cancer
  • Nasopharyngeal cancer
  • Hepatocellular carcinoma
  • Thyroid cancer
CDH16 cadherin 16
CDH3 cadherin 3
  • Adherens junctions interactions
  • Hypotrichosis, congenital, with juvenile macular dystrophy
  • Ectodermal dysplasia, ectrodactyly, and macular dystrophy (EEM syndrome)
CSK C-terminal Src kinase
  • GAB1 signalosome
  • Phosphorylation of CD3 and TCR zeta chains
  • Integrin signaling
  • Co-inhibition by PD-1
  • MAP2K and MAPK activation
  • Signaling by moderate kinase activity BRAF mutants
  • Signaling by high-kinase activity BRAF mutants
  • Signaling by BRAF and RAF1 fusions
  • Paradoxical activation of RAF signaling by kinase inactive BRAF
  • RHOH GTPase cycle
  • Signaling downstream of RAS mutants
  • Signaling by RAF1 mutants
  • Negative regulation of FLT3
  • Dasatinib
  • Staurosporine
  • TG-100801
  • Fostamatinib
CTNNA1 catenin alpha 1
  • Adherens junctions interactions
  • VEGFR2 mediated vascular permeability
  • Myogenesis
  • Myogenesis
  • RHO GTPases activate IQGAPs
  • Regulation of CDH11 function
  • Regulation of CDH19 Expression and Function
  • Regulation of CDH1 Function
  • Degradation of CDH1
  • CDH11 homotypic and heterotypic interactions
CTNNB1 catenin beta 1
  • Degradation of beta-catenin by the destruction complex
  • Beta-catenin phosphorylation cascade
  • TCF dependent signaling in response to WNT
  • Formation of the beta-catenin:TCF transactivating complex
  • Formation of the beta-catenin:TCF transactivating complex
  • LRR FLII-interacting protein 1 (LRRFIP1) activates type I IFN production
  • Apoptotic cleavage of cell adhesion proteins
  • Deactivation of the beta-catenin transactivating complex
  • Synthesis, secretion, and inactivation of Glucagon-like Peptide-1 (GLP-1)
  • Ca2+ pathway
  • Adherens junctions interactions
  • Binding of TCF/LEF:CTNNB1 to target gene promoters
  • Disassembly of the destruction complex and recruitment of AXIN to the membrane
  • Disassembly of the destruction complex and recruitment of AXIN to the membrane
  • VEGFR2 mediated vascular permeability
  • Myogenesis
  • Myogenesis
  • Signaling by GSK3beta mutants
  • CTNNB1 S33 mutants aren't phosphorylated
  • CTNNB1 S37 mutants aren't phosphorylated
  • CTNNB1 S45 mutants aren't phosphorylated
  • CTNNB1 T41 mutants aren't phosphorylated
  • RHO GTPases activate IQGAPs
  • Transcriptional Regulation by VENTX
  • InlA-mediated entry of Listeria monocytogenes into host cells
  • RUNX3 regulates WNT signaling
  • Cardiogenesis
  • Germ layer formation at gastrulation
  • Regulation of CDH11 function
  • Regulation of CDH11 function
  • Regulation of CDH19 Expression and Function
  • Regulation of CDH1 Function
  • Degradation of CDH1
  • Regulation of CDH1 posttranslational processing and trafficking to plasma membrane
  • Formation of paraxial mesoderm
  • Formation of axial mesoderm
  • Formation of definitive endoderm
  • Somitogenesis
  • Regulation of MITF-M-dependent genes involved in pigmentation
  • Regulation of MITF-M-dependent genes involved in cell cycle and proliferation
  • Formation of the nephric duct
  • CDH11 homotypic and heterotypic interactions
  • Specification of the neural plate border
  • High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells
  • Transcriptional and post-translational regulation of MITF-M expression and activity
  • Regulation of PD-L1(CD274) transcription
  • Urea
  • Pilomatricoma; Epithelioma calcificans of Malherbe
  • Gastric cancer
  • Hepatocellular carcinoma
  • Thyroid cancer
  • Colorectal cancer
  • Endometrial Cancer
CTNND1 catenin delta 1
  • Adherens junctions interactions
  • VEGFR2 mediated vascular permeability
  • InlA-mediated entry of Listeria monocytogenes into host cells
  • Regulation of CDH11 function
  • Regulation of CDH11 function
  • Regulation of CDH19 Expression and Function
  • Regulation of CDH1 Function
  • Degradation of CDH1
  • CDH11 homotypic and heterotypic interactions
DSP desmoplakin
  • Apoptotic cleavage of cell adhesion proteins
  • Neutrophil degranulation
  • Keratinization
  • Formation of the cornified envelope
  • RND3 GTPase cycle
  • RND1 GTPase cycle
  • Zinc
  • Artenimol
  • Zinc acetate
  • Striate palmoplantar keratoderma
  • Skin fragility-woolly hair syndrome
  • Arrhythmogenic right ventricular cardiomyopathy (ARVC)
  • Naxos disease and Carvajal syndrome
  • Epidermolysis bullosa simplex, including: Epidermolysis bullosa simplex, Dowling-Meara type (EBS-DM); Epidermolysis bullosa simplex, Koebner type (EBS-K); Epidermolysis bullosa simplex, Weber-Cockayne type (EBS-WC); Epidermolysis bullosa simplex with mottled pigmentation (EBS-MP); Epidermolysis bullosa simplex with migratory circinate erythema; Epidermolysis bullosa simplex, recessive; Epidermolysis bullosa, lethal acantholytic
EGFR epidermal growth factor receptor
  • Signaling by ERBB2
  • Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
  • Signaling by ERBB4
  • SHC1 events in ERBB2 signaling
  • SHC1 events in ERBB2 signaling
  • PLCG1 events in ERBB2 signaling
  • PIP3 activates AKT signaling
  • Signaling by EGFR
  • GRB2 events in EGFR signaling
  • GAB1 signalosome
  • SHC1 events in EGFR signaling
  • EGFR downregulation
  • GRB2 events in ERBB2 signaling
  • PI3K events in ERBB2 signaling
  • EGFR interacts with phospholipase C-gamma
  • EGFR Transactivation by Gastrin
  • Constitutive Signaling by Aberrant PI3K in Cancer
  • Signal transduction by L1
  • Constitutive Signaling by EGFRvIII
  • Inhibition of Signaling by Overexpressed EGFR
  • RAF/MAP kinase cascade
  • ERBB2 Regulates Cell Motility
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
  • ERBB2 Activates PTK6 Signaling
  • Cargo recognition for clathrin-mediated endocytosis
  • Clathrin-mediated endocytosis
  • PTK6 promotes HIF1A stabilization
  • Downregulation of ERBB2 signaling
  • TFAP2 (AP-2) family regulates transcription of growth factors and their receptors
  • Extra-nuclear estrogen signaling
  • NOTCH3 Activation and Transmission of Signal to the Nucleus
  • HCMV Early Events
  • Estrogen-dependent nuclear events downstream of ESR-membrane signaling
  • Signaling by ERBB2 KD Mutants
  • Signaling by ERBB2 ECD mutants
  • Signaling by ERBB2 TMD/JMD mutants
  • Respiratory syncytial virus (RSV) attachment and entry
  • Developmental Lineage of Mammary Gland Myoepithelial Cells
  • Cetuximab
  • Lidocaine
  • Gefitinib
  • Erlotinib
  • Lapatinib
  • Panitumumab
  • Alvocidib
  • IGN311
  • Matuzumab
  • Vandetanib
  • Rindopepimut
  • Canertinib
  • Pelitinib
  • Varlitinib
  • AV-412
  • S-{3-[(4-ANILINOQUINAZOLIN-6-YL)AMINO]-3-OXOPROPYL}-L-CYSTEINE
  • PD-168393
  • Afatinib
  • Osimertinib
  • Necitumumab
  • Foreskin keratinocyte (neonatal)
  • Depatuxizumab mafodotin
  • Icotinib
  • Neratinib
  • Dacomitinib
  • Fostamatinib
  • Poziotinib
  • Zalutumumab
  • Brigatinib
  • Olmutinib
  • Zanubrutinib
  • Abivertinib
  • Mobocertinib
  • Almonertinib
  • Amivantamab
  • Laryngeal cancer
  • Cervical cancer
  • Oral cancer
  • Gastric cancer
  • Choriocarcinoma
  • Esophageal cancer
  • Glioma
  • Bladder cancer
EPHA2 EPH receptor A2
  • EPH-Ephrin signaling
  • EPH-Ephrin signaling
  • EPHA-mediated growth cone collapse
  • EPHA-mediated growth cone collapse
  • EPH-ephrin mediated repulsion of cells
  • EPH-ephrin mediated repulsion of cells
  • RAC1 GTPase cycle
  • RAC2 GTPase cycle
  • RHOG GTPase cycle
  • RHOU GTPase cycle
  • RAC3 GTPase cycle
  • RHOV GTPase cycle
  • RND3 GTPase cycle
  • RND2 GTPase cycle
  • RND1 GTPase cycle
  • Dasatinib
  • Phosphoaminophosphonic Acid-Adenylate Ester
  • Regorafenib
  • Fostamatinib
F2RL2 coagulation factor II thrombin receptor like 2
  • Peptide ligand-binding receptors
  • G alpha (q) signalling events
  • Thrombin signalling through proteinase activated receptors (PARs)
  • Thrombin signalling through proteinase activated receptors (PARs)

Page 2 out of 3 pages